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Abstract
Purpose Intravenously (i.v.) administered nanomedicines
have the potential for tumour targeting due to the enhanced
permeability and retention (EPR) effect, but in vivo tumour
models are rarely calibrated with respect to functional
vascular permeability and/or mechanisms controlling int-
ratumoural drug release. Here the effect of tumour type and
tumour size on EPR-mediated tumour localisation and
cathepsin B-mediated drug release was studied.
Methods Evans Blue (10 mg/kg) and an N-(2-hydroxy-
propyl)methacrylamide (HPMA) copolymer–doxorubicin
(Dox) conjugate (FCE28068) (5 mg/kg Dox-equiv) were
used as probes and tumour levels (and Dox release) mea-
sured at 1 h after i.v. administration in a panel of murine
and human xenograft tumours.
Results Evans Blue and FCE28068 displayed similar
tumour levels in the range of 2–18 % dose/g at 1 h for
B16F10 and L1210. Approximately half of the tumour
models evaluated exhibited tumour size-dependent accu-
mulation of FCE28068; smaller tumours had the highest
accumulation. Administration of free Dox (5 mg/kg) pro-
duced tumour levels of \2.5 % dose/g independent of
tumour size. Whereas the degree of EPR-mediated target-
ing showed *12-fold difference across the tumour models
evaluated, Dox release from FCE28068 at 1 h displayed
*200-fold variation.
Conclusions Marked heterogeneity was seen in terms of
EPR effect and Dox release rate, underlining the need to
carefully calibrate tumour models used to benchmark
nanomedicines against known relevant standard agents and
for optimal development of strategies for late pre-clinical
and clinical development.
Keywords EPR effect  Cathepsin B  Evans Blue 
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Introduction
An increasing number of nanomedicines, including lipo-
somes, polymer conjugates, block copolymer micelles,
nanoparticles and other complex hybrid technologies, are
being developed as anticancer therapeutics, imaging agents
and theranostics (reviewed in [1–4]). Several products are
already in routine clinical use (e.g. Doxil, Abraxane)
with a growing number of technologies including polymer
therapeutics in clinical development [2, 3]. Intravenously
(i.v.) administered long-circulating nanosized constructs
have long been known to exhibit passive tumour targeting
due to the enhanced permeability and retention (EPR)
effect [5, 6]. This phenomenon has been demonstrated in
many in vivo tumour models and the features of polymer
conjugates [7, 8], nanoparticles [4] and block copolymer
micelles [9] governing extravasation, as well as tumour
characteristics [10] regulating the efficiency of the process
have been discussed. Liposomal and polymer conjugate-
based gamma camera imaging probes have also demon-
strated the EPR effect in some tumours in patients [11–13].
A diverse array of tumour pathophysiological features
regulate the efficiency of EPR-mediated tumour targeting
including heterogeneity of intratumoural blood flow,
angiogenic vascular permeability, tumour microenviron-
ment including extracellular matrix features, interstitial
pressure and lymphatic drainage, and thus, no single bio-
marker adequately predicts tumour targeting and/or anti-
tumour activity [14].
As a functional EPR effect is the primary factor gov-
erning nanomedicine tumour access (Fig. 1), it is surprising
that tumour models used to evaluate pharmacokinetics
(PK) and/or antitumour activity have been rarely pre-cali-
brated for this characteristic. This makes comparison of
results, both between experiments and between laborato-
ries, difficult and prevents effective benchmarking of
emerging technologies against those for which there is now
a considerable clinical database. Moreover, although many
constructs have been designed for intratumoural activation,
particularly intralysosomal drug release (using low pH or
lysosomal enzymes such as cathepsin B) (Fig. 1), few
tumour models are calibrated with respect to these acti-
vation mechanisms. Therefore, the aim of this study was to
quantify systematically the early-phase EPR-mediated
tumour targeting using a panel of murine and human
xenograft tumours. The albumin-binding dye Evans Blue,
widely used as a physiological marker of vascular perme-
ability [5], and N-(2-hydroxypropyl)methacrylamide
(HPMA) copolymer–GFLG–Dox (FCE28068) (Fig. 1), a
conjugate that has undergone Phase I/II clinical trials [11,
12], were selected as probes of the EPR effect in tumour
models. In certain experiments, doxorubicin (Dox) alone
was used as a reference control. To establish the
comparability of Evans Blue and FCE28068 as EPR
probes, experiments were initially conducted in a subcu-
taneous (s.c.) B16F10 model previously used widely to
document the PK and antitumour activity of polymer
conjugates [15] and a s.c. L1210 model known to be sen-
sitive to Dox. FCE28068 was then used to quantify the
effect of tumour size on early-phase (1 h) tumour accu-
mulation in a panel of murine and human xenograft
tumours (Table 1) and to study the effect of tumour size on
passive targeting. In addition, as cathepsin B mediates Dox
liberation from FCE28068, and this enzyme is also
responsible for activation of polyglutamic acid anticancer
conjugates currently in clinical trials (e.g. paclitaxel poli-
glumex (PPX) [16]), the extent of Dox released at 1 h was
also quantified. It should be noted that the 1 h time point
was selected for this study as it minimises additional
kinetic effects introduced by differences in blood clearance
rate, probe- or tumour model-dependent tumour efflux rates
and/or inter-tumoural differences in the degradation rate of




HPMA copolymer–GFLG–Dox (FCE28068; also known as
PK1) (MW * 30,000 g/mol; MW/Mn = 1.3; total Dox
6–8 wt%; free Dox \ 1 % in respect of total) and Dox
Table 1 Summary of the tumour models used
Code Type of tumour Mouse
Murine models
L1210 Lymphocytic leukaemia DBA2
B16F10a Melanoma C57 Blk
MAC 15Ab Adenocarcinoma NMRI
MAC 26b Adenocarcinoma NMRI
Meta 7 Lung tumour Balb/c
Human xenografts
RXF 1220 Renal cell carcinoma nu/nu
RXF 486 Renal cell carcinoma nu/nu
PAXF 546 Pancreatic carcinoma nu/nu
MEXF 276 Melanoma nu/nu
MAXF 449 Mammary carcinoma nu/nu
COR L23 Human non-small cell lung carcinoma nu/nu
SK-N-SH Neuroblastoma SCID
IMR 32 Neuroblastoma SCID
SK-N-DZ Neuroblastoma SCID
a [15]
b [14] and for others [17, 29]
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were a gift from Pharmacia and Upjohn, Italy. Evans Blue
was purchased from Sigma, UK. The tumour models used
are summarised in Table 1. B16F10 cells were donated by
Prof. Ian Hart, St. Thomas’s Hospital, London, UK. L1210
cells were from Imperial Laboratories Ltd., UK. Meta-7
and COR L23 cells were from European Collection of Cell
Cultures (ECACC), Wiltshire, UK. C57 black, DBA2,
Balb-c and nu/nu mice were supplied by Bantin and
Kingman Ltd., UK. All animal experiments were per-
formed in accordance with the United Kingdom Co-ordi-
nating Committee on Cancer Research (UKCCCR)
Guidelines for the Welfare of Animals in Experimental
Neoplasia (1998) [17] and with UK Home Office
Guidelines.
Tumour models and administration of probes
All tumours were established as s.c. models (see Table 1
and [14, 15, 17] for full details). Generally, cells were
implanted into the posterior right flank of mice, and the
studies were initiated when tumour reached 25–289 mm2
(product of two diagonal width). MAC 26 tumours were
implanted as tumour pieces [14]. Evans Blue (2 mg/mL in



















Fig. 1 Structure of
a FCE28068, Evans Blue and a
schematic representation of
pendant Dox molecules
conjugated to a nanomedicine
and b a schematic diagram
showing the key steps in tumour
targeting and lysosomotropic
activation
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in PBS; 5 mg/kg Dox-equiv) was administered i.v. via
the tail vein. FCE28068 was given the higher dose of
40 mg/kg Dox-equiv to NMRI mice bearing the murine
adenocarcinomas MAC 15A and MAC 26 to enable
comparison with efficacy experiments in this model [14].
After 1 h, all animals were humanely killed, and tumour
was carefully removed, washed with PBS, weighed and
snap-frozen in liquid nitrogen before extraction and
analysis. It should be noted that most of this study was
conducted according to the 2nd Edition of the UKCCCR
Guidelines for the Welfare of Animals in Experimental
Neoplasia [18], which states that the maximum tumour
burden should not exceed 10 % of the host animal’s
normal body weight or 2.5 g. The initial study involving
measurement of Evans Blue levels in the s.c. L1210
tumour model was conducted prior to the 2nd Edition of
UKCCCR Guidelines, thus accounting the use of
tumours in excess of 2.5 g.
Quantitation of Evans Blue in tumour samples
Evans Blue was extracted from the tumour samples using
a method adapted from Harada et al. (1971) [19]. Briefly,
the tissue samples were blade homogenised in 2 mL of
PBS. The homogenate (1,900 lL) was mixed with
aqueous sodium sulphate solution (0.5 % w/v, 3 mL) and
acetone (7 mL) in polypropylene tubes and then incu-
bated at room temperature (20 C) overnight before
centrifugation (1,0009g, 30 min, 20 C) to precipitate
the tissue. The concentration of Evans Blue in the
supernatant was quantified spectrophotometrically at
590 nm using a standard curve prepared by spiking foetal
bovine serum (FBS) samples with known concentrations
of Evans Blue.
Quantitation of free Dox in tumour samples
Following i.v. administration of free Dox, drug in tumour
samples was quantified using a previously described HPLC
method [20, 21]. Throughout the extraction procedure, all
samples were maintained at 4 C and kept in the dark
(wrapped in foil). Polypropylene tubes and HPLC inserts
were used to minimise adsorption of Dox to containers.
Briefly, tumour samples were thawed, homogenates were
prepared in PBS, and samples (900 lL) were placed in
polypropylene tubes. A daunomycin (Dnm) standard
(donated by Rhoˆne-Poulenc, France) (100 ng, 100 lL) in
PBS was added as an internal standard, followed by
ammonium formate buffer (1 M; pH 8.5; 100 lL) and
chloroform/propan-2-ol (4:1 v/v, 5 mL). After thorough
vortex-mixing (3 9 10 s; within 30 min), the tubes were
centrifuged (1,0009g; 30 min, 10 C). The upper aqueous
layer and tissue pellet were then carefully removed. The
remaining organic phase was evaporated to dryness using a
sample concentrator under constant nitrogen gas (N2) flow
over 20 min. The samples obtained were re-dissolved in
HPLC grade methanol (100 lL) by vortex-mixing (30 s)
and centrifuged (1,0009g, 10 min, 10 C) to remove any
remaining biological materials. Samples (100 lL) were
then analysed by HPLC using a C18 lBondapak
TM column
eluted with propan-2-ol in water (29 % v/v) adjusted to pH
3.2 with orthophosphoric acid with a fluorimetric detector
(excitation 480 nm, emission 560 nm). Data were collected
and analysed using a PowerChrom integrator and software
programme (PowerChrom v 2.0.7). For each experiment, a
Dox standard curve was prepared in parallel.
Quantitation of total HPMA copolymer–Dox
and released free Dox in tumour samples
As HPMA copolymer–Dox does not extract directly into
the organic solvent, free Dox present in the tumour samples
could be extracted and quantified as described above [20,
21]. To quantify HPMA copolymer–Dox, a previously
described acid hydrolysis method [20, 21] was used to first
liberate the Dox aglycone from the conjugate as follows.
Tumours were homogenised in PBS (2,000 lL). Then to
duplicate samples (900 lL), Dnm was added as an internal
standard (500 ng Dnm; 100 lL in PBS) followed by HCl
(2 M, 1 mL) before heating at 80 C for 20 min. Samples
were neutralised by the addition of NaOH (2 M; 1 mL),
ammonium formate buffer (1 M; pH 8.5; 1.5 mL) and then
chloroform/propan-2-ol (4:1 v/v, 5 ml) were added, and the
samples were extracted. HPLC analysis was conducted
exactly as described above for free Dox. To ensure quan-
titation, HPMA copolymer–Dox standards were also ana-
lysed in parallel.
Data expression
Data describing tumour accumulation of Evans Blue or
HPMA copolymer–Dox were expressed as either (i) the %
administered dose per tumour (for the conjugate the value
is given as % Dox-equiv dose administered) or (ii) the
administered dose % dose/g tumour). Data shown are
mean ± SE. Statistical significance was calculated using
Student’s t test for comparison of the mean of two small
samples. Statistical differences of at least p \ 0.05 were
considered statistically significant. To allow comparison
between ‘‘small’’ and ‘‘large’’ tumours, the three smallest
and three largest tumours available were grouped accord-
ing to the classifiers for ‘‘small’’ and ‘‘large’’ described in
the figure legends where tumour size as a variable is
examined.
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Results
Accumulation of Evans Blue, FCE28068 and free Dox
in s.c. B16F10 and L1210 tumours
To assess evidence for the operation of the EPR effect,
intratumour levels of Evans Blue, FCE28028 and Dox
detected at 1 h following i.v. administration in mice
bearing s.c. B16F10 or L1210 tumours are shown in Figs. 2
and 3. When the tumour levels were expressed as % dose
for Evans Blue (Fig. 2a, c), tumour levels increased in an
approximately linear fashion with increasing tumour size
up to a maximum of 4–6 % dose/tumour for the B16F10
model and *15 % dose/tumour for the L1210 model
(Fig. 2a, c). Values measured for Evans Blue and
FCE28028 (Fig. 3a) were quantitatively similar across the
B16F10 tumour size range, as expected for agents requiring
permeable blood vessels for distribution. In contrast,
tumour Dox values measured following i.v. administration
of free drug were consistently much lower (\0.8 % dose
per tumour; Fig. 3c), and expression in terms of % dose/g
tumour tissue showed Dox localisation to be constant
across all tumour sizes studied (in the range 1.1–2.5 %
dose/g tumour; Fig. 3d). In contrast, Evans Blue (Fig. 2b)
and FCE28028 (Fig. 3b) levels expressed as % dose/g
tumour decreased as tumour size increased (Figs. 2b, 3b).
The highest levels of 7.5–18 % dose/g were recorded in the
smallest tumours (B100 mg). Values fell to 0.4–3.7 %
dose/g in the largest tumours ([600 mg; Fig. 3b). The
observed tumour size dependence of Evans Blue accumu-
lation while still evident was less marked in the L1210
model (Fig. 2d). Figure 4 summarises data with respect to
size of B16F10 tumours in relation to accumulated sys-








































































Fig. 2 Levels of Evans Blue detected in s.c. B16F10 and L1210 tumours at 1 h after i.v. administration. a, c Tumour levels expressed as % dose
per tumour and b, d tumour levels expressed as % dose/g/tumour. Each point represents a single tumour sample
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Comparison of FCE28068 levels in murine and human
xenograft tumours
In contrast to the results obtained in the B16F10 models,
when FCE28068 was administered to mice bearing MAC 15A
(8.2–12.6 % dose/g), MAC 26 adenocarcinoma (6.9–10.8 %
dose/g) or Meta-7 lung (3.5–4.7 % dose/g) tumours (Fig. 5),
the amount of conjugate in the tumour did not show statisti-
cally significant changes as tumour size increased. While the
MAC tumours accumulated FCE28068 to a similar degree as
the B16F10 model, approximately two to three lower conju-
gate levels were seen in the Meta-7 lung model (Fig. 5d).
We therefore examined a series of additional models, as
a tumour size-dependent nanomedicine delivery has been
incompletely explored, and the existence of this phenome-
non has important implications for the design of pre-clinical
and clinical studies with nanomedicines. The MEXF 276,
MAXF 449 and RXF 486 human xenograft models
displayed a tumour size-dependent pattern of FCE28068
accumulation (supplemental Fig. 1). Although PAXF 546
showed a similar trend, it should be noted that the three
smallest and the three largest tumours of PAXF 546 pan-
creatic carcinoma tumours did not give statistically
significance different values. In contrast, the RXF 1220,
COR L23, IMR 32, SK-N-SH and SK-N-DZ tumours
(supplemental Fig. 2) displayed size-independent accumu-
lation of FCE28068. (Only two SK-N-DZ tumours were
available, but the data are included for completeness).
Comparison of summary mean values obtained for
FCE28068 accumulation in all the tumour xenografts
(Fig. 6) revealed the highest values in the non-small cell
lung cancer COR L23 (4.7–12.2 % dose/g) and the lowest
values in the larger (0.2–0.4 g) MAXF 449 tumours
(1.0 ± 0.1 % dose/g). Early-phase tumour levels of
FCE28068 across all the xenograft tumours (and sizes)










































































Fig. 3 Levels of FCE28068 and free Dox detected in s.c. B16F10 tumours at 1 h after i.v. administration. a, c Tumour levels expressed as %
dose per tumour, and b, d tumour levels expressed as % dose/g/tumour. Each point represents a single tumour
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Dox released from FCE28068 in murine and human
xenograft tumours
After administration of FCE28068, the free DOX detec-
ted in all tumour samples at 1 h expressed as percentage
of total Dox (i.e. conjugated drug ? free) is shown in
Fig. 7. Only the MAC 15A, MAC 26 murine tumours and
the COR L23 xenograft showed tumour size dependency
in terms of Dox liberation at 1 h. This is interesting as
none of these tumour models displayed tumour size-
dependent FCE28208 levels at 1 h. Dox release was
greater in the smaller tumours, and the difference is
particularly striking for the smaller (\100 mg) COR L23
tumours. Notably, the extent of Dox release in both MAC
tumours was very low (supplemental Fig. 3). Overall,
there were a [200-fold difference in the free Dox levels
seen at 1 h in the murine models studied and a 30-fold
variation in the xenograft models. The fastest Dox release
was observed in B16F10 (22.9 ± 1.2 % at 1 h) and the
smaller in COR L23 tumours (30.1 ± 5.3 %) with the
slowest release rate observed in the larger MAC 26
tumours (0.06 ± 0.01 %) and the SK-N-SH neuroblas-
toma (1.0 ± 0.1 %).
Discussion
In vitro and in vivo pre-clinical models used to screen
novel low molecular weight anticancer agents and biolo-
gics have evolved significantly to better mimic the clinical
disease setting (reviewed in [22, 23]). While these advan-
ces give hope of lead compounds with an increased prob-
ability of a successful clinical outcome, many of the
in vitro and in vivo methods/models used today are not
optimal for nanomedicine evaluation given their very dif-
ferent cellular and whole-body pharmacokinetics compared
to low molecular weight agents (discussed in [2]). Fol-
lowing i.v. administration, low molecular weight drugs
distribute rapidly throughout the body with little or no
tumour selectivity (evidenced here for Dox in Fig. 3d).
After this distribution phase, typically \0.1 % of the
administered drug dose is recoverable in the circulation,
usually in the form of metabolites and/or protein-bound
drug. In contrast, nanomedicines (including liposomes,
polymer conjugates and nanoparticles) are retained within
the bloodstream due to the tight vascular endothelial barrier
present in most organs and limitation of cellular uptake to
the endocytic pathways (discussed in [24]). In the absence
of receptor-mediated targeting, nanomedicine blood clear-
ance is largely governed by the rate of reticuloendothelial
system (RES) uptake and/or renal elimination. Arriving
blood concentration is the primary driver for passive
tumour targeting (Fig. 1b), and a low EPR effect is typi-
cally seen when a nanocarrier is cleared rapidly by pro-
fessional phagocytes. However, it widely recognised that
thereafter vasculature complexity (e.g. different classes of
angiogenic vessels [25], vessel disorganisation and heter-
ogeneity of tumour perfusion) and intratumoural biological
barriers (e.g. high interstitial pressure, the extracellular
matrix, coupled with the presence or absence of lymphatic
drainage, etc. [2, 10, 26]) play an important role in passive
targeting ultimately achieved in any particular tumour
mass.
In the 1950s and 1960s, radio-iodinated albumin and
albumin aggregates were used clinically to image tumours.
Unknowingly, these imaging agents were already capital-
ising on the EPR effect for tumour selectivity [27], as do all
chemotherapeutic and phototherapy agents that bind to
plasma proteins. Using an Evans Blue–albumin complex,
Matsumura and Maeda [5] visualised and quantified
tumour-specific passive accumulation in a Sarcoma 180
model (32 % dose/g tumour at 48 h). In the experiments
reported here, Evans Blue and FCE28068 accumulation by
L1210 and B1F10 (Figs. 2, 3) tumours was in the range
*1–22 % dose/g at 1 h. There was good correlation
between Evans Blue and the nanomedicine FCE 28068
across the tumour size range. The data are in agreement
with the previous reports describing Evans Blue [17],
HPMA copolymer fractions (molecular weight from 4.5 to
800 kDa), PAMAM dendrimer-Dox and liposomal doxo-
rubicin tumour accumulation. Rapid passive targeting gave
similar tumour values (% dose/g) irrespective of polymer





























Fig. 4 Comparison of the levels of FCE28068, Evans Blue and free
Dox detected in small (\100 mg) and large ([400 mg) B16F10
tumours (mean ± SE). Statistical significance *p \ 0.02; n.s. not
significantly different
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A significant observation in these experiments is a
12-fold variation in functional EPR, with many models
displaying tumour size-dependent accumulation. The
higher tumour localisation was noticeably in the smaller
tumours, and this maybe a reflection of greater angiogenic
activity in smaller tumours, reduced or absent tumour
blood supply in hypoxic regions of larger necrotic tumours,
an increase in tumour interstitial fluid pressure as the
tumour grows, or a combination of all of these factors.
111In-DTPA-labelled PEGylated liposomes injected i.v. to
mice bearing KB human head and neck squamous cell
xenografts also displayed tumour levels inversely corre-
lated with tumour size: 15.1 ± 10.8 % dose/g in tumours of
\0.1 g and 3.0 ± 1.3 % dose/g in tumours of[1 g [31]. In
this regard, the current results of experiments raise the
possibility of a novel development strategy for nanomedi-
cines, focusing on systemic delivery of such constructs in
the adjuvant setting or with ‘‘small-volume’’ metastatic
disease after surgical debulking.
Whatever the mechanism, there is a growing body of
evidence that nanosized vectors show greatest targeting to
the smaller tumours and this could provide an important
opportunity to localise to those micrometastases so difficult
to diagnose and treat effectively. Use of 111In-DTPA-
labelled PEGylated liposomes to image 17 patients with
locally advanced cancers [13] gave positive tumour images
in 15/17 patients and tumour levels in the range of
*0.5–3.5 % dose at 72 h. Highest liposome localisation
was observed in patients with head and neck cancers





































































(c) Meta 7-FCE28068 (d)
Fig. 5 FCE28068 levels in MAC 15A, MAC 26 and Meta-7 tumours
at 1 h after i.v. administration. The data in a–c individual tumour
samples and d a comparison of the levels after measured in the three
smallest and three largest tumours. The distribution of FCE 28608 for
the B16F10 model is shown for comparison. In Fig. 5 ‘‘small’’
B16F10, MAC 15A MAC 26 and Meta-7 tumours were \100, \470,
\480 and \150 mg, respectively. ‘‘Large’’ B16F10, MAC 15A,
MAC 26 and Meta-7 tumours were [400, [900, [1,000 and
[300 mg, respectively. Statistical significance ** p \ 0.02; ns not
significantly different
424 Cancer Chemother Pharmacol (2013) 72:417–427
123
FCE2068 in Phase I clinical studies [11]) and lower levels
in breast cancers (*0.005 % injected dose/g). The breast
tumours were larger than the lung tumours, supporting a
relationship between small tumour site and improved
localisation, but the relationship was not unequivocal as it
was noted that some tumours of similar size but different
histological type displayed different levels of liposomal
uptake. Using 99mTc-DTPA-labelled PEGylated liposomes
that localised to lung and head and neck cancers [32],
others have suggested a correlation between tumour tar-
geting and microvessel density as defined by anti-CD31
staining. Although tumour vessel density (VEGF expres-
sion) does correlate with tumour vascular permeability
(Evans Blue) in some human tumour xenografts [17], other
studies have indicated that a more complex multifactorial
mechanism underpins EPR-mediated targeting and effi-
cacy, e.g. inflammatory status. At this time, it is difficult to
predict tumour localisation/antitumour activity using a
single biomarker [14].
Overexpression of lysosomal thiol-dependent proteases
in many human tumours has been well documented [33],
and these enzymes play an important role in tumour pro-
gression (e.g. metastasis and angiogenesis). A growing
number of polymer conjugates are being designed for
lysosomotropic delivery [34, 35] and cathepsin B-mediated
drug release [1, 2]. The wide variation in early-phase Dox
release from FC28068 (*200-fold) observed here illus-
trates the need to characterise tumour models around the
basis for delivery to tumours and response of tumours to
nanomedicines as part of evolving an optimal clinical
strategy for their development. For example, retrospective
analysis of clinical data from PPX Phase III trials in
advanced lung cancer patients [36] showed improved sur-
vival in female but not in male patients, and it has been
postulated that patient oestradiol level might play a pivotal
role as oestrogens are known to induce cathepsin B activ-
ity. Earlier studies involving FCE28068 in s.c. B16F10
tumours [15, 37] indicated an *30 min time lag before
Dox release began, supporting the hypothesis of drug



















Fig. 6 Comparison of the levels of FCE28068 detected in small and large
human xenograft tumours at 1 h (mean ± SE, n = 3). Tumour model
size cut-offs (mg small, mg large) are as follows: MEXF276 (\50,[200);
MAXF449 (\50, [200), PAXF 546 (\100, [500), RXF 486 (\100,
[600), RXF 1220 (\100,[400), CORL 23 (\100,[400), IMR32 (\120,
[220). Statistical significance *p \ 0.05 ***p \0.01, ns not signifi-
cantly different. For the full data set, see Supplementary Figs. 1 and 2


































Fig. 7 Comparison of the DOX released from FCE28068 in the different
tumour models. Panel (a) murine tumour models (mean ± SE, n = 3).
Statistical significance: **p \ 0.02; ***p \ 0.01; ns not significantly.
Panel (b) human xenograft models (mean ± SE, n = 3; except SK-N-
SH, n = 5 and SK-N-DZ, n = 2). Statistical significance: ** p \ 0.02;
ns not significantly different. Tumour size classification as per Figs. 4
and 6
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release following endocytic internalisation [38]. However,
it should be noted that other factors may play a role in
controlling the rate of drug release: (i) rate of conjugate
diffusion through the tumour interstitium [39], (ii) the rate
of endocytic internalisation (endocytic gateways and
intracellular trafficking pathways are often dysregulated in
cancer [40]) and (iii) exposure to cathepsin B in the
extracellular milieu. This complexity underlines the
importance of functional tumour calibration in terms of
drug release and also the future role of the real-time tumour
imaging techniques that are emerging for quantitation of
proteolysis per se [41] and polymer degradation [42].
Conclusions
The wide variation in passive targeting (% dose/g) and Dox
liberation observed here (1 h) highlights the need to cali-
brate in vivo tumour models in respect of these parameters
before they are used to define pharmacokinetics and/or
antitumour activity of nanomedicines. This would provide
more clinically relevant models for optimisation of lead
candidates and benchmarking performance against anti-
cancer nanomedicines already in routine clinical use [2].
Evans Blue is a useful tool for routine evaluation of passive
targeting, and the 1 h time point enables comparison of
different nanocarriers minimising complications arising
due to different blood clearance rate, tumour efflux and
intratumoural degradation of the probe over time. These
observations also emphasise the potential to select patients
for early clinical trial involving nanomedicine therapy that
are most likely to respond, i.e. by use of clinical imaging to
verify functional EPR [43], and monitoring of tumour
biopsy samples for biomarkers relevant to activating con-
ditions, e.g. in this case cathepsin B.
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